ROCKVILLE, Md.--(BUSINESS WIRE)--Bacilligen, Inc. announced today the receipt of a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), a component of the US National Institutes of Health (NIH). The project, entitled Improved Bladder Cancer Therapy With Recombinant BCG, aims to improve the safety and efficacy of an existing immunotherapy, BCG, that can have difficult side effects that prevent some patients from successfully utilizing the treatment. Some patients do not respond to BCG at all. Bacilligen’s product will exhibit increased potency and reduced side effects in patients thus permitting more patients to complete their treatment course and improve the treatment success rate. Like BCG, Bacilligen’s improved recombinant version, called rMB, will be targeted for use in both treatment and prevention of recurrence of superficial bladder cancer.
